CellSeed Inc.
7776
Rank in Stocks
#23401
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell... CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
Share Price
$1.06
Last synced: 2026-11-13
Market Cap
$41.75M
Change (1 day)
-0.12%
Change (1 year)
-59.10%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade CellSeed Inc. (7776)
Category
Healthcare
Operating Margin for CellSeed Inc. (7776)
Operating Margin as of November 2026 TTM: -1,472.32%
According to CellSeed Inc.'s latest financial reports, its current operating margin (TTM) is -1,472.32%. At the end of 2025 the company had an operating margin of -1,250.18%.
Operating Margin history for CellSeed Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,472.32% | 17.77% |
| 2025 | -1,250.18% | 185.49% |
| 2024 | -437.91% | 19.32% |
| 2023 | -366.99% | -37.57% |
| 2022 | -587.86% | 9.99% |
| 2021 | -534.48% | 48.17% |
| 2020 | -360.72% | 20.46% |
| 2019 | -299.46% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -99.87% |
US
|
|
| 33.87% | -100.02% |
US
|
|
| -116.04% | -99.92% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.02% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about CellSeed Inc.'s operating margin
What is CellSeed Inc.'s operating margin?
CellSeed Inc.'s operating margin is -1,472.32%, as of Nov 2026.
What was CellSeed Inc.'s operating margin in 2025?
In 2025, CellSeed Inc.'s operating margin was -1,250.18%, compared with -437.91% in 2024.
How has CellSeed Inc.'s operating margin changed since 2020?
From 2020 to 2025, CellSeed Inc.'s operating margin was highest in 2020 (-360.72%) and lowest in 2025 (-1,250.18%).
How does CellSeed Inc.'s operating margin compare with similar companies?
CellSeed Inc.'s operating margin (-1,472.32%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.